Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the stent endothelialization (> 20 microns) of VIVO ISARTM versus XIENCE SkypointTM stents at 1-month (very early strut covered) at follow-up by Optical Coherence Tomography (OCT) implanted IN THE SAME PATIENT during routine clinical practice.
To evaluate the stent endothelialization (> 20 microns) of VIVO ISARTM versus XIENCE SkypointTM stents at 1-month (very early strut covered) at follow-up by Optical Coherence Tomography (OCT) implanted IN THE SAME PATIENT during routine clinical practice.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| VIVO ISAR DES in the first lesion | Experimental |
| |
| XIENCE Skypoint DES in the first lesion | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| VIVO ISAR DES implanted in the First lesion, XIENCE Skypoint DES implanted in the Second lesion | Device | VIVO ISAR DES implanted in the First lesion, XIENCE Skypoint DES implanted in the Second lesion |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of early Covered struts (≥ 20μm) at 1 month OCT after stent implantation | Percentage of early Covered struts (≥ 20μm) at 1 month OCT after stent implantation | 1 month |
| Percentage of stents with uncovered struts at 1 month OCT after stent implantation | Percentage of stents with uncovered struts (0μm) at 1 month OCT after stent implantation | 1 month |
| Mean thickness of struts tissue coverage at 1 month OCT after stent implantation | Mean thickness of struts tissue coverage at 1 month OCT after stent implantation | 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of malapposition of stent at 1 month OCT after stent implantation | Percentage of malapposition of stent at 1 month OCT after stent implantation | 1 month |
| Percentage of covered struts at 1 months OCT after stent implantation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Express refusal of the patient to participate in the study
Patients with ST elevation Myocardial Infarction or Cardiogenic Shock
Patients with high thrombotic content
Pregnant or breastfeeding patients
Patients with complex PCI (Percutaneous Coronary Intervention )(defined as):
Severe calcified lesion (need to use prior complex techniques of calcium modification such as intravascular lithotripsy, rotational/orbital atherectomy, laser.
Patients with malignant neoplasms or other comorbid conditions with life expectancy <12 months
Patients with a target lesion in a bypass graft
Lesions due to restenosis
Patients with PCI in the target vessel in the previous 9 months
Patients with contraindication or difficulty to evaluate in the follow-up with OCT (renal failure, excessive tortuosity or lesions aorto-ostial)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Universitari Vall D'Hebron | Barcelona | 08035 | Spain | |||
| Hospital Clinic Barcelona |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29544956 | Background | Koppara T, Tada T, Xhepa E, Kufner S, Byrne RA, Ibrahim T, Laugwitz KL, Kastrati A, Joner M. Randomised comparison of vascular response to biodegradable polymer sirolimus eluting and permanent polymer everolimus eluting stents: An optical coherence tomography study. Int J Cardiol. 2018 May 1;258:42-49. doi: 10.1016/j.ijcard.2018.01.011. | |
| 30082261 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| XIENCE Skypoint DES implanted in the First lesion, VIVO ISAR DES implanted in the Second lesion | Device | XIENCE Skypoint DES implanted in the First lesion, VIVO ISAR DES implanted in the Second lesion |
|
Percentage of covered struts at 1 months OCT after stent implantation
| 1 month |
| All-Cause Death Rate at 6 months | All-Cause Death Rate at 6 months | 6 months |
| Cardiac Death Rate at 6 months | Cardiac Death Rate at 6 months | 6 months |
| Myocardial Infarction Rate at 6 months | Myocardial Infarction Rate at 6 months | 6 months |
| Target vessel revascularization Rate at 6 months | Target vessel revascularization Rate at 6 months | 6 months |
| Neointimal Healing Score (NHC) by OCT at 1 month | The NHS is then calculated as follows:
| 1 months |
| Percentage of malapposed total struts at 1 month | Percentage of malapposed total struts at 1 month | 1 month |
| Percentage of malapposed scaffold struts over side branch at 1 month | Strut malapposition: Measured maximum distance ≥100 μm between the strut surface and adjacent vessel surface by OCT, considering thickness of scaffold, was defined as malapposition. As a result, scaffold malapposition is defined as the presence of any malapposed struts. The ratio of malapposed struts (% malapposed strut) was the ratio of malapposed struts from total analyzable struts. | 1 month |
| Barcelona |
| 08036 |
| Spain |
| Hospital Universitario de Gerona Doctor Josep Trueta | Girona | 17007 | Spain |
| Hospital Universitari de Bellvitge | L'Hospitalet de Llobregat | 08907 | Spain |
| Asano T, Jin Q, Katagiri Y, Kogame N, Takahashi K, Chang CC, Chichareon P, Wang C, Shi B, Su X, Fu G, Wu Y, Zhou X, Yuan Z, Wykrzykowska JJ, Piek JJ, Serruys PW, Onuma Y, Chen Y. A randomised comparison of healing response between the BuMA Supreme stent and the XIENCE stent at one-month and two-month follow-up: PIONEER-II OCT randomised controlled trial. EuroIntervention. 2018 Dec 20;14(12):e1306-e1315. doi: 10.4244/EIJ-D-18-00461. |
| 36740229 | Background | Andreasen LN, Balleby IR, Barkholt TO, Hebsgaard L, Terkelsen CJ, Holck EN, Jensen LO, Maeng M, Dijkstra J, Antonsen L, Kristensen SD, Tu S, Lassen JF, Christiansen EH, Holm NR. Early healing after treatment of coronary lesions by thin strut everolimus, or thicker strut biolimus eluting bioabsorbable polymer stents: The SORT-OUT VIII OCT study. Catheter Cardiovasc Interv. 2023 Mar;101(4):787-797. doi: 10.1002/ccd.30579. Epub 2023 Feb 5. |
| 35472561 | Background | Otaegui Irurueta I, Gonzalez Sucarrats S, Barron Molina JL, Perez de Prado A, Massotti M, Carmona Ramirez MA, Marti G, Bellera N, Serra B, Serra V, Domingo E, Lopez-Benito M, Sabate M, Ferreira Gonzalez I, Garcia Del Blanco B. Can an ultrathin strut stent design and a polymer free, proendothelializing probucol matrix coating improve early strut healing? The FRIENDLY-OCT trial. An intra-patient randomized study with OCT, evaluating early strut coverage of a novel probucol coated polymer-free and ultra-thin strut sirolimus-eluting stent compared to a biodegradable polymer sirolimus-eluting stent. Int J Cardiol. 2022 Aug 1;360:13-20. doi: 10.1016/j.ijcard.2022.04.043. Epub 2022 Apr 25. |
| Background | Massberg S, Byrne RA, Kastrati A, Schulz S, Pache J, Hausleiter J, et al. Polymerfree sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISARTEST 5) trial. Circulation. 2 de agosto de 2011;124(5):624-32. 18. Kufner S, Sorges J, Mehilli J, Cassese S, Repp J, Wiebe J, et al. Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial. JACC Cardiovasc Interv. 25 de abril de 2016;9(8):784-92. |
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided